Vicente Merino-Bohorquez
Overview
Explore the profile of Vicente Merino-Bohorquez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
113
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moreno-Mellado E, Aslan A, Akova M, Leon E, Merchante N, Vinuesa D, et al.
Clin Microbiol Infect
. 2025 Jan;
PMID: 39832652
Objectives: The FOSFOMIC study assessed the clinical and microbiological effectiveness, and safety of intravenous fosfomycin in treating complicated urinary tract infections (cUTIs) caused by Escherichia coli, in comparison with other...
2.
Delgado Romero J, Soto-Retes L, Cisneros Serrano C, Blanco-Aparicio M, Ferrando Piqueres R, Diaz-Perez D, et al.
Open Respir Arch
. 2024 Dec;
7(1):100375.
PMID: 39717141
No abstract available.
3.
Gonzalez-Antuna J, Valdes-Delgado T, Maldonado-Perez B, Belvis-Jimenez M, Castro-Laria L, Merino-Bohorquez V, et al.
Therap Adv Gastroenterol
. 2024 Sep;
17:17562848241271980.
PMID: 39257470
Background: Ustekinumab (UST) is an effective treatment option in Crohn's disease (CD) and ulcerative colitis (UC). However, it still remains unclear if therapeutic drug monitoring could be helpful to guide...
4.
Martin V, de la Haba R, Lopez-Cornejo P, Lopez-Lopez M, Antonio Lebron J, Bernal E, et al.
Int J Pharm
. 2024 Aug;
664:124593.
PMID: 39168289
The goal of this work is to investigate if the synergistic antifungal activity between cyclosporine A, CsA, and voriconazole, VRZ, increases when both drugs are encapsulated in a nanocarrier as...
5.
Merino-Bohorquez V, Berisa-Prado S, Delgado-Valverde M, Tirado-Perez M, Garcia-Palomo M, Alonso-Herreros J, et al.
Farm Hosp
. 2024 May;
48(4):T145-T152.
PMID: 38782645
Objective: To study the physicochemical and microbiological stability over 90 days of two preservative-free methylprednisolone sodium succinate (MTPSS) 1 and 10 mg/mL eye drops for use in ocular pathologies such...
6.
Vazquez-Sanchez R, Navarro-Davila M, Ramirez Herraiz E, Merino-Bohorquez V, Borras-Blasco J, Onteniente-Gonzalez A, et al.
Expert Opin Biol Ther
. 2024 May;
24(7):647-653.
PMID: 38698351
Background: The rise of biologic agents has been a major breakthrough in treating immune-mediated inflammatory diseases (IMIDs). However, their high cost underscores the need for strategies to optimize treatment efficiency....
7.
Salvador-Martin S, Rubbini G, Vellosillo P, Zapata-Cobo P, Velasco M, Palomino L, et al.
Biomed Pharmacother
. 2024 Feb;
173:116299.
PMID: 38401525
Background/aims: Changes in gene expression profiles among individuals with inflammatory bowel diseases (IBDs) could potentially influence the responsiveness to anti-TNF treatment. The aim of this study was to identify genes...
8.
Rodriguez-Ochoa J, Perez-Palacios P, Merino-Bohorquez V, Ortiz-Padilla M, Velazquez-Escudero A, Rodriguez-Bano J, et al.
J Antimicrob Chemother
. 2024 Feb;
79(4):784-789.
PMID: 38334407
Background: Temocillin is an old antimicrobial that is resistant to hydrolysis by ESBLs but has variable activity against carbapenemase-producing Enterobacteriaceae. The current EUCAST susceptibility breakpoints for Enterobacterales are set at...
9.
Martinez-Moragon E, Antepara Ercoreca I, Munoz Garcia M, Casas Maldonado F, Calvin Lamas M, Chiner Vives E, et al.
J Asthma
. 2023 Dec;
61(6):619-631.
PMID: 38146964
Objective: The study aimed to reach a consensus on the most relevant patient-reported outcomes (PROs), the corresponding measures (PROMs), and measurement frequency during severe asthma patient follow-up. Methods: Two Delphi...
10.
Valdes-Delgado T, Aguado-Paredes A, Merino-Bohorquez V, Martin-Manzanares J, Alonso M, Maldonado B, et al.
Dig Dis Sci
. 2023 Nov;
69(1):228-234.
PMID: 37943382
Background: Therapeutic drug monitoring of infliximab levels in patients with inflammatory bowel disease (IBD) optimizes patients' treatment. The reference technique is based on enzyme-linked immunosorbent assay (ELISA) although point of...